Back to top
more

Encompass Health (EHC)

(Real Time Quote from BATS)

$103.32 USD

103.32
255,544

+1.41 (1.38%)

Updated Nov 7, 2024 01:33 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat

by Zacks Equity Research

Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.

Encompass Health (EHC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Encompass Health (EHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Encompass Health (EHC) Q2 Earnings Beat Estimates

by Zacks Equity Research

Encompass Health (EHC) delivered earnings and revenue surprises of 9.90% and 0.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare

by Zacks Equity Research

Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

Astrana Health, Inc. (ASTH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Astrana Health, Inc. (ASTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Unlocking Q2 Potential of Encompass Health (EHC): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Encompass Health (EHC) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

by Zacks Equity Research

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?

by Zacks Equity Research

Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.

Encompass Health (EHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View

by Zacks Equity Research

HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.

Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?

by Zacks Equity Research

Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.

UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter earnings continue to be supported by strong Optum and UnitedHealthcare business lines. Rising medical costs partially offset the positives.

Why Encompass Health (EHC) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Encompass Health (EHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia

by Zacks Equity Research

Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.

Here's Why Encompass Health (EHC) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Humana (HUM) Ties Up With PsychArmor for Better Veteran Care

by Zacks Equity Research

Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.

Encompass Health (EHC) Expands in Louisville With New Rehab Unit

by Zacks Equity Research

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

Encompass Health (EHC) Gains 30% in a Year: More Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of sustained top-line growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.

Here's Why Investors Must Hold on to Centene (CNC) Stock Now

by Zacks Equity Research

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Why Encompass Health (EHC) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Should Value Investors Buy Encompass Health (EHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?

by Zacks Equity Research

Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.